Table 1 Clinicopathological characteristics of pT3a prostate carcinomas with regards to SARIFA-status
SARIFA-status | ||||||||
|---|---|---|---|---|---|---|---|---|
Variable | All cases | SARIFA-positive | SARIFA-negative | |||||
n = 301 | 100% | n = 178 | 59% | n = 123 | 41% | p-value | ||
Age in years, at surgery, median (range) | 68 (46–87) | 68 (52–87) | 68 (46–83) | 0.336 | ||||
iPSAa (mean ± standard deviation), in ng/ml | 14.85 ± 15.19 | 17.41 ± 18.39 | 11.28 ± 7.80 | 0.004 | ||||
pN category | pN0 | 212 | 70% | 119 | 67% | 93 | 76% | 0.162 |
pN1 | 87 | 29% | 57 | 32% | 30 | 24% | ||
NA | 2 | 1% | 2 | 1% | 0 | 0% | ||
Gleason Score | 6 | 11 | 4% | 3 | 2% | 8 | 7% | 0.015 |
7 | 183 | 61% | 107 | 60% | 76 | 62% | ||
8 | 48 | 16% | 24 | 14% | 24 | 20% | ||
9 | 53 | 18% | 39 | 22% | 14 | 11% | ||
10 | 6 | 2% | 5 | 3% | 1 | 1% | ||
Lymphatic invasion | L0 | 216 | 72% | 128 | 72% | 88 | 72% | 0.079 |
L1 | 26 | 9% | 20 | 11% | 6 | 5% | ||
NA | 59 | 20% | 30 | 17% | 29 | 24% | ||
Vascular invasion | V0 | 230 | 76% | 140 | 79% | 90 | 73% | 0.137 |
V1 | 12 | 4% | 9 | 5% | 3 | 2% | ||
NA | 59 | 20% | 29 | 16% | 30 | 24% | ||
Perineural invasion | Pn0 | 8 | 3% | 4 | 2% | 4 | 3% | 0.449 |
Pn1 | 252 | 84% | 153 | 86% | 99 | 81% | ||
NA | 41 | 14% | 21 | 12% | 20 | 16% | ||
R status | R0 | 172 | 57% | 93 | 52% | 79 | 64% | 0.039 |
R1 | 129 | 43% | 85 | 48% | 44 | 36% | ||
Extraprostatic extension | focal | 158 | 52% | 82 | 46% | 76 | 62% | < 0.001 |
non-focal | 97 | 32% | 39 | 22% | 7 | 6% | ||
NA | 46 | 15% | 57 | 32% | 40 | 33% | ||